Precision BioSciences, Inc. (DTIL)
After hours:
| Previous Close | 10.41 |
| Open | 10.60 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 10.13 - 10.73 |
| 52 Week Range | 8.25 - 27.03 |
| Volume | |
| Avg. Volume | 131,992 |
| Market Cap | 72.482M |
| Beta (5Y Monthly) | 1.57 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024
DURHAM, N.C., May 01, 2024--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that the company will present late-breaking preclinical data from its clinical candidate, PBGENE-HBV, for the treatment of chronic hepatitis B (HBV) during a poster presentation at the European Association
- Business Wire
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
DURHAM, N.C., April 16, 2024--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company, today announced the anticipated return of three programs from Prevail Therapeutics Inc., a wholly owned subsidiary of Eli Lilly and Company. Precision exercised its option to regain rights for the programs following Prevail Therapeutics’ decision to conclude the collaboration. Precision uses its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated g
- Business Wire
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
DURHAM, N.C., March 27, 2024--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided a business update.
